KANE BIOTECH INC

Micro‑cap biotech Kane Biotech (KNE.V) remains flat at CAD 0.03, focusing on breakthrough biofilm‑disruption tech that could impact medical devices, water treatment and food safety.

Canadian biotech Kane Biotech faces a fragile future as its market‑making deal offers little real value, leaving investors cautious about its slow‑moving biofilm tech.

Explore Kane Biotech’s flat 24‑hour market performance and its pioneering biofilm‑dispersal tech in Winnipeg, Canada.